Immuneering reports 17.3mo OS in pancreatic cancer; Q2 net loss $17.3M

Immuneering Corp

Net loss of $17.3M ($0.27/share) in Q2 2026 vs $14.4M ($0.40/share) in Q2 2025; R&D expenses rose to $14.0M from $10.5M.
Cash, equivalents and marketable securities $182.7M as of June 30, 2026, down from $217.0M at Dec 31, 2025; runway into 2029.
Phase 3 MAPKeeper 301 trial of atebimetinib + mGnP in first-line pancreatic cancer is dosing patients; over 30 study locations posted.
Phase 2a data at ASCO showed 17.3-month median overall survival in 55 patients; 84% weight stable or gained weight at 3 months.
Appointed Andrew Gengos as CFO; he previously served as CFO of Terns Pharmaceuticals (acquired by Merck for $6.7B).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.